CA2516097A1 - A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent - Google Patents

A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent Download PDF

Info

Publication number
CA2516097A1
CA2516097A1 CA002516097A CA2516097A CA2516097A1 CA 2516097 A1 CA2516097 A1 CA 2516097A1 CA 002516097 A CA002516097 A CA 002516097A CA 2516097 A CA2516097 A CA 2516097A CA 2516097 A1 CA2516097 A1 CA 2516097A1
Authority
CA
Canada
Prior art keywords
edotecarin
pharmaceutically acceptable
cancer
acceptable salt
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002516097A
Other languages
English (en)
French (fr)
Inventor
Marina Ciomei
Enrico Pesenti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia Italia S.P.A.
Marina Ciomei
Enrico Pesenti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia S.P.A., Marina Ciomei, Enrico Pesenti filed Critical Pharmacia Italia S.P.A.
Publication of CA2516097A1 publication Critical patent/CA2516097A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
CA002516097A 2003-02-21 2004-02-16 A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent Abandoned CA2516097A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000317A ITMI20030317A1 (it) 2003-02-21 2003-02-21 Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
ITMI2003A000317 2003-02-21
PCT/EP2004/050130 WO2004073719A1 (en) 2003-02-21 2004-02-16 A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent

Publications (1)

Publication Number Publication Date
CA2516097A1 true CA2516097A1 (en) 2004-09-02

Family

ID=32894164

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002516097A Abandoned CA2516097A1 (en) 2003-02-21 2004-02-16 A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent

Country Status (10)

Country Link
EP (1) EP1599210A1 (de)
JP (1) JP2006518355A (de)
AR (1) AR043241A1 (de)
BR (1) BRPI0407642A (de)
CA (1) CA2516097A1 (de)
CL (1) CL2004000319A1 (de)
IT (1) ITMI20030317A1 (de)
MX (1) MXPA05008879A (de)
TW (1) TW200500073A (de)
WO (1) WO2004073719A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ575388A (en) * 2006-10-06 2012-03-30 Bn Immunotherapeutics Inc Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441026B1 (en) * 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
ES2273841T3 (es) * 2000-02-28 2007-05-16 Pfizer Enterprises Sarl Combinacion sinergica para el tratamiento de cancer colorrectal.

Also Published As

Publication number Publication date
WO2004073719A1 (en) 2004-09-02
JP2006518355A (ja) 2006-08-10
CL2004000319A1 (es) 2005-04-22
BRPI0407642A (pt) 2006-03-01
TW200500073A (en) 2005-01-01
AR043241A1 (es) 2005-07-20
EP1599210A1 (de) 2005-11-30
MXPA05008879A (es) 2005-10-05
ITMI20030317A1 (it) 2004-08-22

Similar Documents

Publication Publication Date Title
EP3066101B1 (de) Kombinationstherapie gegen krebs mit einer bromdomäne und extraterminalen (bet)-proteinhemmern
Ajani et al. A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma
MXPA01010138A (es) Docetaxel en combinacion con rhumas her2 para el tratamiento de canceres.
JP2012500180A5 (de)
JP2014132009A5 (de)
KR20160023816A (ko) 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도
JP2002507571A (ja) アントラサイクリン誘導体とカンプトテシン誘導体の相乗組合せを含有する抗腫瘍組成物
JP2003533485A5 (de)
US20100311774A1 (en) Combination Comprising Paclitaxel for Treating Ovarian Cancer
JP2009536956A (ja) 抗癌治療法
KR20130118981A (ko) 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물
JP2019508433A (ja) Ｌｉｖ１−ａｄｃ及び化学療法剤を用いた併用療法
JP2706371B2 (ja) 癌治療用補助剤及びそれを用いたキット
JP6591665B2 (ja) Ｔ−ｄｍ１難治性がん患者のｓｙｄ９８５処置
JP4672257B2 (ja) エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用
US6562834B2 (en) Combination comprising camptothecin and a stilbene derivative for the treatment of cancer
CA2516097A1 (en) A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent
TW201306833A (zh) 包含康布列塔司他汀（ｃｏｍｂｒｅｔａｓｔａｔｉｎｓ）族衍生物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之組合
KR20210039414A (ko) 암의 치료를 위한 병용 요법
AU2002216029A1 (en) A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
KR20210150470A (ko) A-노르-5α안드로스테인 화합물계 약물 및 항암제의 병용
ZA200508696B (en) Use of irinotecan for treatment of resistant breast cancer
KR20210039413A (ko) 암의 치료를 위한 병용 요법
US20230029336A1 (en) Combination Therapy for Treating a Hematological Malignancy
WO2008135792A1 (en) Pm00104 compound for use in cancer therapy

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead